



GOBIERNO
DE ESPAÑA

MINISTERIO
DE SANIDAD, CONSUMO
Y BIENESTAR SOCIAL

BIOCIDES DAY

Helsinki, 29 October 2019


Revitalising the Review Programme Member State actions Spain


M Luisa González Márquez
Ministry of Health, Consumer Affairs and Social Welfare
Spain



Review Programme in Spain

Active substance	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	
A		In progress				In progress			In progress		In progress	In progress	In progress										
B							In progress	Finalized	In progress	In progress													
C	Finalized	Finalized	Finalized	Finalized		Finalized	In progress		In progress	In progress			Finalized										
D				Finalized																			
E		In progress				In progress					In progress	In progress											In progress
F														Finalized									
G																			In progress	In progress			
H		In progress					In progress		In progress														
I						In progress					In progress												
J								Finalized															
K																				Finalized			
L																			In progress	In progress			
M						In progress					In progress	In progress	In progress										
N								Finalized											Finalized				
O		In progress	In progress	In progress	In progress																		

 Finalized


 In progress



Delays do not only affect to ES


AS/PT combination - EU

■ Pending AS/PT ■ Approved AS/PT



AS/PT combination - ES

■ Pending AS/PT ■ Approved AS/PT





Delays due to:

- Technical difficulties: Identity, technical equivalence, redefinition...
- Causes due to applicants: Disagreements between applicants, delays in providing complementary data...
- Two regulations that directly impacted the RP:
 - Regulation 1062/2014
 - Regulation 2017/2100
- Economic crisis in Spain that affected the public sector. Loss of resources.



The Active Substances Workshop held in February 2019 marked a turning point in the work approach of the Review Program



Actions taken by ES CA

- Staff increase - Training actions planning
- Work planning – Prioritization
- Meetings with several applicants
- Communications through R4BP3 giving deadlines
- Reactivation of the files - collaboration with DM
- Meeting with Contact Point in ECHA
- Nomination of WG Member



ECHA offered us to collaborate with:

- Contact Point: Help for prioritization, identification of bottlenecks...
- Training activities in ECHA for national experts with real cases. They suggest that is possible also with MS
- Facilitation for attending WG by teleconference
- Support in the evaluation of dossiers, through consultation to experts in ECHA:
 - Technical equivalence
 - Endocrine disruption
 - ENV Exposure
 -



Up to now, we take advantage of:

- Meeting Contact Point – ES Evaluation Team
- Early comments on one ET report
- And on one ED report – TC with ED expert

And we are thinking about:

- Training activities in ECHA for national experts with real cases
- Consultation to ENV exposure experts



Review Programme in Spain

Next steps

Active substance	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	
A		Subsequent target				Next to be finished			Subsequent target		Subsequent target	Subsequent target	Next to be finished										
B							In progress	Finalized	In progress	In progress													
C	Finalized	Finalized	Finalized	Finalized		Finalized	In progress		In progress	In progress			Finalized										
D				Finalized																			
E		Subsequent target				Subsequent target					Subsequent target	Subsequent target											In progress
F														Finalized									
G																							
H		In progress					In progress		In progress														
I						In progress					In progress												
J							Finalized																
K																							Finalized
L																							Next to be finished
M						In progress					In progress	In progress	In progress										
N							Finalized																Finalized
O		Subsequent target	Subsequent target	Subsequent target	Subsequent target																		



Finalized



Subsequent target



Next to be finished




In progress




AS/PT combination - Next provision

■ Pending AS/PT ■ Approved AS/PT ■ Planned AS/PT




AS/PT combination - Subsequent target

■ Pending AS/PT ■ Approved AS/PT
■ Planned AS/PT



AS/PT combination - ¿???

■ Pending AS/PT ■ Approved AS/PT





Concomitant tasks

- Active substance received due to Brexit
- CLH reports
- Renewals



What we expect for future:

- We expect good collaboration with:
 - ECHA
 - Applicants
 - Other MS
- We expect hard work
- No more crisis



What we expect for future:

- Review Programme should finish in 2024
- Only collaborative work can allow us to reach the maximum possible in meeting the target





GOBIERNO
DE ESPAÑA

MINISTERIO
DE SANIDAD, CONSUMO
Y BIENESTAR SOCIAL

Thank you for your attention